Oncogenic signalling through mechanistic Target Of Rapamycin (mTOR): a driver of metabolic transformation and cancer progression

Rad, Ellie, Murray, James and Tee, Andrew ORCID: https://orcid.org/0000-0002-5577-4631 2018. Oncogenic signalling through mechanistic Target Of Rapamycin (mTOR): a driver of metabolic transformation and cancer progression. Cancers 10 (1) 10.3390/cancers10010005

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Throughout the years, research into signalling pathways involved in cancer progression has led to many discoveries of which mechanistic target of rapamycin (mTOR) is a key player. mTOR is a master regulator of cell growth control. mTOR is historically known to promote cell growth by enhancing the efficiency of protein translation. Research in the last decade has revealed that mTOR’s role in promoting cell growth is much more multifaceted. While mTOR is necessary for normal human physiology, cancer cells take advantage of mTOR signalling to drive their neoplastic growth and progression. Oncogenic signal transduction through mTOR is a common occurrence in cancer, leading to metabolic transformation, enhanced proliferative drive and increased metastatic potential through neovascularisation. This review focuses on the downstream mTOR-regulated processes that are implicated in the “hallmarks” of cancer with focus on mTOR’s involvement in proliferative signalling, metabolic reprogramming, angiogenesis and metastasis

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	MDPI AG
ISSN:	2072-6694
Date of First Compliant Deposit:	15 January 2018
Date of Acceptance:	28 December 2017
Last Modified:	06 May 2023 13:47
URI:	https://orca.cardiff.ac.uk/id/eprint/108173

Citation Data

Cited 35 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item